1
|
- 1910.1030(c)(1)(v) - Applicability of the Bloodborne Pathogens standard during transection of the umbilical cord.
|
2
|
- 1910.1030(c)(1)(v) - OSHA's position on the use of Novartis' Fluvirin device.
|
3
|
- 1910.1030(c)(1)(v) - Requirements for safety-engineered sharps for stockpiled pandemic influenza vaccines and pre-filled syringes.
|
4
|
- 1910.1030(c)(1)(v) - Limiting factors for implementing the use of engineering controls, i.e., safety scalpels, under the Bloodborne Pathogens standard.
|
5
|
- 1910.1030(c)(1)(v) - Bloodborne Pathogens Standard application to bifurcated needles; acceptability and appropriateness of safety bifurcated needles.
|
6
|
- 1910.1030(c)(1)(v) - Clarification from OSHA regarding the use of the NeedleguardTM in a hospital environment.
|
7
|
- 1910.1030(c)(1)(v) - Engineering control requirements for allergy and immunization injections.
|
8
|
- 1910.1030(c)(1)(v) - Needlestick Safety and Prevention Act and the requirement to include safety-engineered sharps devices in pre-packaged surgical kits or trays.
|
9
|
- 1910.1030(c)(1)(v) - Safer medical devices must be selected based on employee feedback and device effectiveness, not Group Purchasing Organizations.
|